Published June 30, 2014 | Version v1
Journal article Open

Cancer Stem- Like Cells in Melanoma Progression, Resistance and Recurrence: Significance for Melanoma Treatment

  • 1. Cancer Institute, University of Mississippi Medical Center, Jackson, MS 39216, USA, Institut National de la Santé et de la Recherche Médicale, U 977, Department of Operative Dentistry and Endodontics, Dental Faculty, University of Strasbourg, 67000 Strasbourg, France
  • 2. Cancer Institute, University of Mississippi Medical Center, Jackson, MS 39216, USA
  • 3. Institut National de la Santé et de la Recherche Médicale, U 977, Department of Operative Dentistry and Endodontics, Dental Faculty, University of Strasbourg, 67000 Strasbourg, France
  • 4. Clinic of Dermatology, University Hospital of Aachen, Pauwelsstr. 30, 52074 Aachen, Germany

Description

Human malignant melanoma is a highly aggressive tumor which demonstrates heterogeneity and a propensity to drug resistance. Despite improved treatment options, patients with advanced malignant melanoma continue have a poor prognosis as measured by progression-free and overall survival. The cancer stem-like cell (CSC) hypothesis suggests that neoplastic clones are maintained by a small fraction of cells with stem cell properties. As has been demonstrated with other tumor types, melanoma progression, resistance
to chemo- and radiotherapy, and recurrence can be attributed to a small fraction of cells termed melanoma stem-like cells (MSCs). These MSCs are characterized by a distinct protein patterns and aberrant signaling pathways, which are either in a causal or consequential relationship to tumor progression, drug resistance and recurrence. This review focuses on the mechanistic role of MSCs leading to tumor progression and metastasis, resistance and recurrence. Understanding the molecular mechanisms underlying MSCs migration, invasion, resistance to standard treatments, and recurrence may help to improve current therapeutic modalities and/or pave the way for the development of new therapeutical management strategy for tumor treatment.

Files

IJST-2328-3548-02-401.pdf

Files (543.4 kB)

Name Size Download all
md5:7b86a18c5be157786a5893b3c5934fa1
543.4 kB Preview Download